Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30848995 | 1.00 | LMNA (0.51) | LMNAMEN1KMT2AHTTTSHR | |
| SCHEMBL14684937 | 0.87 | LMNA (0.43) | LMNAMEN1KMT2AHTTMAPT | |
| SCHEMBL30224794 | 0.87 | AKR1C3 (0.41) | LMNAMEN1KMT2AHTTTSHR | |
| SCHEMBL7425083 | 0.86 | ALDH1A1 (0.57) | LMNAMEN1KMT2AHTTTSHR | |
| SCHEMBL5201986 | 0.84 | LMNA (0.49) | LMNAMEN1KMT2AHTTMAPT | |
| SCHEMBL1694828 | 0.84 | MAPT (0.49) | LMNAMEN1KMT2AHTTTSHR | |
| SCHEMBL5092015 | 0.84 | LMNA (0.49) | LMNAMEN1KMT2AHTTMAPT | |
| SCHEMBL31085600 | 0.83 | LMNA (0.53) | LMNAMEN1KMT2AHTTMAPT | |
| SCHEMBL31085599 | 0.83 | LMNA (0.53) | LMNAMEN1KMT2AHTTMAPT | |
| SCHEMBL15270721 | 0.83 | LMNA (0.53) | LMNAMEN1KMT2AHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289785-A1 | INDOLE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF | MITOIMMUNE THERAPEUTICS INC. (KR) | 2025-09-18 | — | — | US | disclosed |
| US-20250172566-A1 | SACCHARIDE SENSING SYSTEMS | Carbometrics Limited (GB) | 2025-05-29 | — | — | US | disclosed |
| US-20250122155-A1 | NOVEL INDOLE DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | MITOIMMUNE THERAPEUTICS INC. (KR) | 2025-04-17 | — | — | US | disclosed |
| EP-4469803-A1 | SACCHARIDE SENSING SYSTEMS | Carbometrics Limited (GB) | 2024-12-04 | — | — | EP | disclosed |
| CN-118847245-A | Synthesis method of bromoalkyl substituted quinoxaline | 烟台宁远药业有限公司 | 2024-10-29 | — | — | CN | disclosed |
| EP-4382524-A1 | INDOLE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF | MitoImmune Therapeutics Inc. (KR) | 2024-06-12 | — | — | EP | disclosed |
| EP-4382523-A1 | NOVEL INDOLE DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | MitoImmune Therapeutics Inc. (KR) | 2024-06-12 | — | — | EP | disclosed |
| CN-117794917-A | Novel indole derivatives, pharmaceutical compositions containing the same and uses thereof | 水疗免疫疗法有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117794922-A | Indole derivatives, process for their preparation and their use | 水疗免疫疗法有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-114478497-B | Arylalkyl acid GLP-1 receptor agonists and uses thereof | 杭州中美华东制药有限公司 | 2023-10-20 | — | — | CN | disclosed |
| WO-2005123050-A2 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-29 | — | — | WO | disclosed |
| US-20050282805-A1 | thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-22 | — | — | US | disclosed |
| EP-1007037-A4 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2004-10-06 | — | — | EP | disclosed |
| US-6677369-B2 | CARBOXIMIDAMIDE DERIVATIVE ANTICOAGULANTS INHIBIT FACTOR XA | ELI LILLY AND COMPANY | 2004-01-13 | — | — | US | disclosed |
| US-20030195223-A1 | An anticoagulant, blood inhibitor of factor Xa, a N1-amidinebenzoyl- N2-benzoyl-1,2-benzenediamine derivatives; chemical intermediates | BEIGHT DOUGLAS WADE (US) | 2003-10-16 | — | — | US | disclosed |
| US-6417200-B1 | BLOOD COAGULATION FACTOR XA IN MAMMALS | ELI LILLY AND COMPANY | 2002-07-09 | — | — | US | disclosed |
| EP-1007037-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999000127-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | WO | disclosed |
| US-4767769-A | HISTAMINE-H2 ANTAGONISTS | THE BOOTS COMPANY PLC (GB) | 1988-08-30 | — | — | US | disclosed |
| EP-0172631-A1 | Therapeutic agents | The Boots Company PLC (GB) | 1986-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195223-A1 | An anticoagulant, blood inhibitor of factor Xa, a N1-amidinebenzoyl- N2-benzoyl-1,2-benzenediamine derivatives; chemical intermediates | F12, F11, F2 | LMNA 415/4885MEN1 611/4885KMT2A 2684/4885 |
| US-20250289785-A1 | INDOLE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF | AIFM2, AIFM1, HMOX1 | LMNA 1625/4885MEN1 813/4885KMT2A 4547/4885 |
| US-20250172566-A1 | SACCHARIDE SENSING SYSTEMS | GALE, SLC2A8, SLC2A4 | LMNA 4421/4885MEN1 1771/4885KMT2A 4482/4885 |
| US-20250122155-A1 | NOVEL INDOLE DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | AIFM2, AIFM1, FECH | LMNA 2515/4885MEN1 1362/4885KMT2A 4608/4885 |
| US-20050282805-A1 | thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide | F11, TFPI, F12 | LMNA 500/4885MEN1 1744/4885KMT2A 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.